This activity was planned in collaboration by the Elsevier Office of Continuing Medical Education and ASiM. Thank you for your participation. All information provided improves the scope and purpose of our programs.

You must complete this evaluation form to receive acknowledgement for completing this activity.

PoorFairGoodVery goodExcellent
IDENTIFY key differences between biosimilar agents and their reference biologic, including clinical data needed for approval.
REVIEW policy guidance on biosimilars, including naming and considerations for interchangeability.
ASSESS the most up-to-date evidence on efficacy, safety and clinical implications of biosimilars as part of RA management.
NeverRarelySometimesMost of the TimeAlwaysN/A
Consider prescribing biosimilars in your biologic-naïve patients with rheumatoid arthritis.
Consider switching from reference biologics to biosimilars in your patients with rheumatoid arthritis.
NeverRarelySometimesMost of the TimeAlwaysN/A
Consider prescribing biosimilars in your biologic-naïve patients with rheumatoid arthritis.
Consider switching from reference biologics to biosimilars in your patients with rheumatoid arthritis.
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Overall, this activity met my learning needs
The information presented was without promotional or commercial bias
The content provided a fair and balanced coverage of the topic
Was scientifically rigorous and evidence based
Provided appropriate and effective opportunities for active learning (e.g., discussion, Q & A)
Promoted improvements or quality in healthcare
The quality of the educational process was satisfactory and appropriate
The information provided with regard to faculty financial relationships met my needs for disclosure
The format of the discussion was relevant and enhanced my competence to treat patients with rheumatoid arthritis
The faculty/speakers were knowledgeable and presented the information clearly
PoorFairGoodVery goodExcellent
Roy Fleischmann, MD, MACR
Professor Jürgen Braun
Stanley Cohen, MD
An application has been made to the EACCME® for European accreditation of this activity. A status change to this application will be communicated via email to all attendees looking to receive European external CME credits for attending this activity. The Elsevier Office of Continuing Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. I participated in this CME activity and claim _______ credits